Kythera Biopharmaceuticals, Inc (KYTH)

[DewDiligence]

AGN-KYTH deal amended to be all-cash at $75/sh:

#msg-115964045

[Dave1865]

Seems like a low offer given that one analyst has given it a price of $85 within one year.

[tedkov]

Kythera Biopharmaceuticals Sued by Shareholder Over Merger Bid - (via NewsPoints Desk)

June 19, 2015
Tags: NewsPoints Kythera Allergan United States Corporate Affairs Mergers &
Acquisitions

A Kythera shareholder, filed a lawsuit in Delaware Chancery Court attempting
to block the $2.1 billion purchase of the company by Allergan.
The shareholder accused Kythera’s board of breach of fiduciary duties, arguing
that the purchase price is insufficient in light of the company's growth
prospects and that deal-protection clauses in the agreement preclude other
companies from submitting successful competing offers.
Kythera did not immediately respond to requests for a comment.
To contact the law firm on behalf of shareholders of
Kythera for more information call toll free 800.511.7037

[WF]

Been thinking about this. There may be another offer come in which might push the $75 offer higher. I'm going to hang for a while.

[WF]

She thanks you.

[Cbdpotential]

Great story! Smart wife

[WF]

I listened to my wife!

One night a few weeks ago the local news ran a piece on this new drug that had been approved for double-chins and neck fat problems. She said right then, "You better buy that stock. Women will pay up for those injections to improve their aging faces and avoid expensive plastic surgery." So, next day I bought the stock at about $45. Sold August Calls for income at $55. (Big mistake). Bought another 100 shares at $55 and sold more August 65 Calls for income. (Another mistake.). Meanwhile nice gains and nice income from the calls to lower average cost of shares. Looked at the stock this morning and saw the price at $74+ and how much my calls had gone against my gains. Gulp! Then I calculated the delta between the loss in the Calls and the gain on the shares. Delta $1000 in my favor. As I was trying to decide whether to buy the calls back (first time for me to do this), I decided to look at the news to see what was driving the stock up. BUYOUT AT $75. SCORE!! No way to lose now if I buy the calls and the price goes down unless the deal goes through. Only upside for a counter-offer. So, I pulled the trigger!

It's been an exciting morning. Thanks for listening to my story.

Moral of story is listen to your wife once in a while. )

My lucky day!!

WF

[Cbdpotential]

Mistake. Should have been buying! A lot!

[Cbdpotential]

Kicking myself for not jumping in earlier...

[DewDiligence]

AGN acquires KYTH for $75/sh in cash+stock:

#msg-114666378

Congrats to KYTH longs.

[tedkov]

BUYOUT OF KYTHERA - LAW FIRM SEEKS HIGHER PRICE
fyi….

New York, New York/June 17, 2015 - A leading national securities and shareholder rights law firm announces that it is investigating the acquisition of Kythera Biopharmaceuticals on behalf of its shareholders. Allergan has agreed to acquire KYTHERA in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion. The fixed-value transaction consideration will be payable 80 percent in cash and 20 percent in new AGN shares issued to KYTHERA shareholders.

The investigation concerns whether shareholders are receiving the maximum value for their shares considering the company's future growth prospects. Indeed, analysts have projected the stock is worth at least $85 per share. The investigation further seeks to determine whether management may have entered into this transaction for their own self interests at the expense of the company's shareholders.

If you are a shareholder of Kythera and would like to receive additional information regarding this matter including how your shares can be eligible for a higher price at no cost or expense please contact us toll free at 800.511.7037.

[KingDMC]

Insider buying 2 weeks ago making sense now..

[stocktrademan]

$KYTH recent news/filings

bullish

## source: finance.yahoo.com

Tue, 09 Jun 2015 10:14:12 GMT ~ Coverage initiated on Kythera Biopharma by Guggenheim


read full: http://finance.yahoo.com/q/ud?s=KYTH
*********************************************************

Sat, 06 Jun 2015 02:14:08 GMT ~ KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program

[at noodls] - WESTLAKE VILLAGE, Calif., June 05, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that on June 2, 2015, the Compensation Committee of the Company's Board of Directors ...

read full: http://www.noodls.com/view/29E575DFEE7E455AD38894FBF873D08412251089
*********************************************************

Sat, 06 Jun 2015 01:40:00 GMT ~ KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program

[GlobeNewswire] - WESTLAKE VILLAGE, Calif., June 05, 2015-- KYTHERA Biopharmaceuticals, Inc. today announced that on June 2, 2015, the Compensation Committee of the Company’ s Board of Directors granted 50 new employees ...

read full: http://finance.yahoo.com/news/kythera-biopharmaceuticals-grants-stock-options-014000484.html
*********************************************************

Thu, 04 Jun 2015 17:37:37 GMT ~ KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders


read full: http://biz.yahoo.com/e/150604/kyth8-k.html
*********************************************************

Wed, 03 Jun 2015 21:21:11 GMT ~ KYTHERA Biopharmaceuticals to Present at the Goldman Sachs 36th Annual Global Healthcare Conference

[at noodls] - WESTLAKE VILLAGE, Calif., June 03, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that John Smither, chief financial officer, will present at the Goldman Sachs ...

read full: http://www.noodls.com/view/1AE7012CBD2253D559A73F306CEC64D5A703EEAB
*********************************************************

$KYTH charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$KYTH company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/KYTH/company-info
Ticker: $KYTH
OTC Market Place: Not Available
CIK code: not found
Company name: Kythera Biopharmaceuticals, Inc.
Incorporated In:

Business Description:

$KYTH share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$KYTH extra dd links

Company name: Kythera Biopharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/KYTH/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/KYTH/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=KYTH+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=KYTH+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=KYTH+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/KYTH/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/KYTH/news - http://finance.yahoo.com/q/h?s=KYTH+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/KYTH/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/KYTH/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/KYTH/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/KYTH/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/KYTH/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/KYTH/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/KYTH/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/KYTH/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=KYTH+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/KYTH
DTCC (dtcc.com): http://search2.dtcc.com/?q=Kythera+Biopharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Kythera+Biopharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Kythera+Biopharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/KYTH/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/KYTH
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/KYTH/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/KYTH/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/KYTH/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/KYTH/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/KYTH/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/KYTH/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/KYTH/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=KYTH&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=KYTH
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/KYTH/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=KYTH+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=KYTH+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=KYTH
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=KYTH
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=KYTH+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/KYTH/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=KYTH+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/KYTH.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=KYTH
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/KYTH/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/KYTH/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/KYTH/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/KYTH/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/KYTH
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/KYTH
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/KYTH:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=KYTH
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=KYTH



$KYTH DD Notes ~ http://www.ddnotesmaker.com/KYTH

[Cbdpotential]

Watching

[SamLevi]

Quite surprised, nice gain A/H tho

[DewDiligence]

FDA approves Kybella (ATX-101), but shares close down 4%:

#msg-113218056

[Tdash]

I wonder if this will hit $60. since it will open at $55

[jav0033]

2/10 Kythera Biophrarma has entered into separate license agreements with Actelion Pharmaceuticals Ltd. and the University of Pennsylvania for a novel approach for the treatment of hair loss, which together could enable KYTHERA to bring a new treatment to the very large and still highly unsatisfied hair loss market.

[DewDiligence]

ATX-101 PDUFA date is 5/13/15: #msg-104183063.

[mr_sano]

Wow how does this company fetch this lofty of pps? One product in the pipe with huge overhead and r/d that's going to consume its $$. I know running a trail can be expensive but these guys can spend some money!

[DewDiligence]

Bayer sells ex-US rights to ATX-101: #msg-98577791.

[boo boo]

For those paying attention, that gap did fill!

[surf1944]

9:01AM Kythera Biopharma announces additional positive efficacy and patient satisfaction data from ATX-101 Phase III trials for the reduction of submental fat (KYTH) 45.89 : Co announced additional patient satisfaction and efficacy data from REFINE-1 and REFINE-2, two pivotal Phase III clinical trials of ATX-101 for the reduction of submental fat, which commonly presents as a double chin.

The new data demonstrates that the majority of ATX-101 subjects reported satisfaction with their treatment as well as improvements on visual and psychological impacts of their "chin fat." Additionally, the vast majority of subjects had a reduction in submental fat as assessed independently by clinicians and patients, and most adverse events were transient, local to the treatment area, and mild to moderate in severity.

KYTHERA's recent REFINE-1 and REFINE-2 top line data announcement showed that both pivotal trials met all their pre-defined primary and secondary endpoints and demonstrated high statistical significance across these measures (p < 0.001). The patient satisfaction data presented at ASDS supplement the top line data and demonstrate that 88.9% of REFINE-1 and 84.2% of REFINE-2 ATX-101 treated subjects reported satisfaction with treatment received in the trial, compared to 37.7% and 43.6% of placebo subjects, respectively (p < 0.001).

[boo boo]

Gonna exit my position here. Either the gap fills or we consolidate and setup for the next run, IMO.

[surf1944]

Kythera price target raised to $50 from $34 at Leerink
Theflyonthewall.comTheflyonthewall.com – 2 hours 8 minutes ago

Leerink raised its price target for Kythera after the company reported better than expected results for its REFINE-1 and REFINE-2 studies of ATX-101. The firm says a 4% dropout rate is a "very good sign" and keeps an Outperform rating on the stock.

[DewDiligence]

Questions about ATX-101 safety:

#msg-87872157
#msg-87872909
#msg-87873366

[surf1944]

12:53AM Kythera Biopharma presents positive MRI results from Phase IIb study of ATX-101 in the Reduction of Submental Fat or 'Double Chin' (KYTH) 22.46 : Co presents positive results that found MRI measurements of patients treated with ATX-101 demonstrated a statistically significant reduction in submental fat, commonly known as double chin. MRI assessments were performed in the study as a quantifiable and objective measure of submental fat volume and thickness. The same study also demonstrated positive results based on validated clinician- and patient-reported outcome measures.

Results from the Phase IIb study showed that patients treated with 2 mg/cm2 of ATX-101 demonstrated:

Reduction of submental fat o Patients achieved statistically significant reduction in submental fat thickness as measured from baseline vs. placebo based on MRI (week 16 and 32, respectively)
Statistically significant improvement in self-evaluated visual and psychological impact of submental fat vs. placebo based on Patient-Reported Submental Fat Impact Scale (overall impact, week 32)
Most adverse events were of mild to moderate intensity, transient and primarily associated with the treatment area

[surf1944]

1:34AM Kythera Biopharma reports positive interim results from open-label Phase IIIb study of ATX-101 (KYTH) 20.35 : Co reports positive interim results from a Phase IIIb, multicenter, evaluating the safety and efficacy of ATX-101, a potential first-in-class, non-surgical, injectable drug in Phase III trials for the reduction of unwanted submental fat, commonly known as "double chin." The results found that ATX-101 is well tolerated and may be effective in reducing SMF by both clinician- and patient-reported outcome measures.

Observations were made using validated rating instruments for which one-grade changes are considered to be clinically meaningful:

Reduction of submental fat:
87% of patients achieved at least a one-grade improvement from baseline on the Clinician-Reported Submental Fat Rating Scale
Similarly, 83% of patients achieved at least a one-grade improvement on the Patient-Reported Submental Fat Rating Scale
96% of patients had unchanged or improved skin laxity based on the clinician rated Submental Skin Laxity Grading Scale
97% of patients reported improvement in chin and neck definition
Adverse events were primarily of mild to moderate intensity, transient and associated with the treatment area

[boo boo]

Weird. Just goes to show you what little effort it takes to move this one. Still no news that I can find. Must've got caught up in the bank selloff bullshit from yesterday. Looking good this morning.

[boo boo]

Yep, my service said circuit breakers were activated, which caused the stock to be halted.

[jakeb]

Some sort of hft flash crash?

$KYTH loses 33% in 1/2 second. 85 trades, 13,150 shares. 11 exchanges participate. 6 orders canceled for each trade. #HFT

— Eric Scott Hunsader (@nanexllc) March 18, 2013

[jakeb]

No idea. Down almost 10% today. Seems odd on no news at all.

[boo boo]

Any news as to why stock was halted? Looks like missed buy op.

[surf1944]

1:32AM Kythera Biopharma provides positive interim results from open-label study of ATX-101 in the reduction of unwanted submental fat (KYTH) 25.12 : Co announces positive interim results from a Phase IIIb, multi-center, open-label study to evaluate the safety and efficacy of ATX-101, an investigational injectable drug for the reduction of unwanted submental fat, commonly known as double chin. The results found that ATX-101 is well-tolerated and may be effective in reducing SMF by both clinician and patient reported outcome measures. The ATX-101 global clinical development program has enrolled more than 2,500 total patients, of which more than 1,500 have been treated with ATX-101. In this open-label Phase IIIb study, interim results three months after the last ATX-101 treatment found:

Reduction of submental fat o 87%of patients achieved at least a one-grade improvement from baseline on the Clinician-Reported Submental Fat Rating Scale
Similarly, 83%of patients achieved at least a one-grade improvement on the Patient-Reported Submental Fat Rating Scale
96%of patients had unchanged or improved skin laxity based on the clinician rated Submental Skin Laxity Grading Scale
95%of patients were satisfied with treatment based on the Global Post Treatment Satisfaction Scale
Adverse events were of mild to moderate intensity, transient and primarily associated with the treatment area

[boo boo]

Looking for initial entry btwn $26/7.

[surf1944]

KYTHERA Biopharmaceuticals Added to Russell 3000, 2000, Global and Microcap Indexes
December 26, 2012

LOS ANGELES, December 26, 2012 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that the company has been added to each of the broad-market Russell 3000® Index, the Russell 2000® Index, the Russell Microcap® Index and the Russell Global® Index as part of Russell's quarterly IPO additions effective as of the close of trading on December 21, 2012.

"We're extremely pleased to be included in these widely known Russell indexes,” said Keith Leonard, KYTHERA’s President and CEO. “We are committed to building long-term value for our stockholders and we value the significance and increased visibility within the investment community that can result from inclusion in these indexes.”

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $3.9 trillion in institutional assets currently are benchmarked to them.

The annual reconstitution of Russell’s U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Membership in the Russell 3000 Index, which remains in place for one year, means automatic inclusion in either the large-cap Russell 1000® Index or small-cap Russell 2000 Index, as well as the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes. The Russell 3000 Index also serves as the U.S. component of the Russell Global® Index. More information about Russell Indexes is available at www.russell.com/indexes.

[surf1944]

http://seekingalpha.com/article/916851-ipo-preview-kythera-biopharmaceuticals?source=yahoo

[surf1944]

6:48AM Kythera Biopharma prices upsized 4.4 mln share IPO at $16.00 per share, at upper end of $14-16 expected range (KYTH) : Co initially planned to offer 4.0 mln shares.